AstraZeneca (LSE:AZN) Reports Positive TEZSPIRE Phase 3 Results, Is The Discount Too Wide?

AstraZeneca's Phase III trial for ATTR-CM treatment showed no benefit over stabilizers. STAT News reports. The drug is part of the multibillion-dollar heart disease market. Separately, a US appeals court upheld the FDA's decision to end shortages of Novo Nordisk and Eli Lilly diabetes/obesity drugs, limiting compounded-drug manufacturers' production.

Alnylam Pharmaceuticals (ALNY) shares dropped 6% after AstraZeneca's Phase 3 trial for a silencer drug targeting ATTR-CM failed, showing no improvement in patients already on stabilizer drugs. The results raise concerns about silencer drugs in the competitive ATTR-CM treatment market, which is expected to be worth billions.

AstraZeneca's Phase 3 trial for a heart disease drug (a silencer) failed, showing no benefit for patients already on stabilizers. The study involved ATTR-CM patients and was conducted with Ionis Pharmaceuticals. The results may impact other companies like Alnylam and BridgeBio, which also market ATTR-CM drugs.

AstraZeneca and Amgen's Tezspire met main and secondary goals in a Phase 3 trial for eosinophilic esophagitis (EoE), according to the companies. They plan to share data with regulators, aiming for approval. Tezspire is already approved for severe asthma and chronic rhinosinusitis with nasal polyps. Analysts project global sales of $2.7B this year, growing to $3.3B by 2027, with EoE approval adding further revenue potential.

Amgen and AstraZeneca's asthma drug, Tezspire, showed positive results in treating eosinophilic esophagitis, a condition affecting 470,000 U.S. patients. The drug demonstrated significant improvement by week 24, according to the companies.

AstraZeneca (AZN) and Amgen (AMGN) announced that Tezspire met primary goals in a late-stage trial for eosinophilic esophagitis, showing reduced inflammation and improved swallowing. Despite the positive results, shares of both companies declined. Tezspire is approved for severe asthma and generated $1.13B in sales for AZN in 2025. The companies await results from two cancer trials seen as more critical for growth.